Abstract:Background: Ciprofloxacin is usually used in the treatment of lower respiratory tract infections (LRTIs). Recent studies abroad have shown ciprofloxacin is inadequately dosed and might lead to worse outcomes. The aim of this study was to perform pharmacokinetic and pharmacodynamic analyses of ciprofloxacin in elderly Chinese patients with severe LRTIs caused by Gramnegative bacteria. Methods: From September 2012 to June 2014, as many as 33 patients were empirically administered beta-lactam and ciprofloxacin combination therapy. Patients were in fused with 200 or 400 mg of ciprofloxacin every 12 h, which was determined empirically by the attending physician based on the severity of the LRTI and the patient's renal condition. Ciprofloxacin serum concentrations were determined by high-performance liquid chromatography. Bacterial culture was performed from sputum samples and/or endotracheal aspirates, and the minimum inhibitory concentrations (MICs) of ciprofloxacin were determined. The ratios of the area under the serum concentration-time curve to the MIC (AUC/MIC) and of the maximum serum concentration of the drug to the MIC (C-max/MIC) were calculated. The baseline data and pharmacokinetic parameters were compared between clinical success group and clinical failure group, bacteriologic success group and bacteriologic failure group. Results: Among the 33 patients enrolled in the study, 17 were infected with Pseudomonas aeruginosa, 14 were infected with Acinetobacter baumannii, and two were infected with Klebsiella pneumoniae. The mean age of the patients was 76.9 +/- 6.7 years. Thirty-one patients (93.4%) did not reach the target AUC/MIC value of >125, and 29 patients (87.9%) did not reach the target C-max/MIC value of >8. The AUC/MIC and C-max/MIC ratios in the clinical success group were significantly higher than those in the clinical failure group (61.1 [31.7-214.9] vs. 10.4 [3.8-66.1], Z= -4.157; 9.6 [4.2-17.8] vs. 1.3 [0.4-4.7], Z= -4.018; both P< 0.001). The AUC/MIC and C-max/MIC ratios in the patients for whom the pathogens were eradicated were significantly higher than those in the patients without the pathogens eradicated (75.3 [31.7-214.9] vs. 10.5 [3.8-66.1], Z. 3.938; 11.4 [4.2-17.8] vs. 1.4 [0.4-5.4], Z.-3.793; P < 0.001 for both). Receiver operating characteristic curve analysis showed that the AUC/MIC and C-max/MIC values were closely associated with clinical and bacteriologic efficacies (P < 0.001 in both). Conclusions: Ciprofloxacin is inadequately dosed against Gram-negative bacteria, especially for those with relatively high MIC values. Consequently, the target values, AUC/MIC > 125 and C-max/MIC > 8, cannot be reached.

PK/PD of pazufloxacin against pathogen from community acquired infection

Study on the optimization of pazufloxacin in clinical application based on PK/PD theory

Analysis of bacterial distribution and antimicrobial susceptibility of community-acquired urinary tract infection

Causative Agent Distribution and Antibiotic Therapy Assessment among Adult Patients with Community Acquired Pneumonia in Chinese Urban Population.

Pharmacokinetics of Pazufloxacin Mesilate in Chinese Healthy Volunteers

Dosing regimen selection for pazufloxacin tablet in clinical trial based on its pharmacokinetic/pharmacodynamic analysis

Pharmacokinetics of pazufloxacin mesilate sodium chloride for injection

Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.

A clinical randomized controlled trial of pazufloxacin injection in treatment of bacterial infection in 111 patients

Pharmacokinetics study of pazufloxacin mesylate in single dose in Chinese healthy volunteers

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia.

Pharmacokinetics of Pazufloxacin Mesilate Sodium Chloride in healthy Chinese volunteers after intravenous injection

Pharmacokinetics of pazufloxacin single dose intravenous in healthy volunteers

Pharmacokinetic study of Pazufloxacin in the plasma in Chinese healthy volunteers

Pharmacokinetics of Pazufloxacin Injection in Healthy Volunteers

Clinical pharmacokinetics and pharmacodynamics of gemifloxacin in healthy Chinese volunteers following multiple oral administration

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia

Pharmacokinetics Study of Pazufloxacin Mesilate after Multiple Doses in Chinese Healthy Volunteers

Parmacokinetics of pazufloxacin mesilate sodium chloride injection in Chinese healthy volunteers

Pharmacokinetic and pharmacodynamic analysis of flomoxef against the clinical isolates of strains